Special Issue

Recent Advances in Peptide-Based Vaccines

Message from the Guest Editor

Using entire organism-based vaccines has various potential disadvantages such as induction of allergy, autoimmunity, and antibody-dependent enhancement in some cases. On the other hand, peptide-based vaccines are more specific, safe, and cost-effective. These peptides can be engineered and manufactured to resemble specific immunogenic antigens of pathogenic agents. In addition, peptide-based vaccines have attracted much interest in the development of novel vaccines to treat certain chronic diseases such as Alzheimer's disease and cancer, providing protective responses and limiting the administration of therapeutics. However, peptide-based vaccines have a low immunogenic effect and therefore need potent immune-stimulating adjutants and specialized delivery carriers such as nanoparticles or fused to immunogenic carriers. This Special Issue focuses on the recent advances in peptide-based vaccines, including peptide identification, immunogenic effect and adjuvant agents, and selected delivery systems.

Guest Editor

Dr. Hussin Rothan

Department of Biology, Georgia State University, Atlanta, GA 30302, USA

Deadline for manuscript submissions

closed (15 October 2021)

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/si/52491

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines

Vaccines

an Open Access Journal by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed

mdpi.com/journal/vaccines

About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp
Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

MDPI